Skip to main content

Advertisement

Log in

The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis

  • Laboratory Investigation - Human/Animal Tissue
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Leptomeningeal carcinomatosis (LC) is a devastating complication of cancer. Intrathecal administration of cytotoxic chemotherapy adds little to survival which is measured in weeks. The potential toxicities and efficacy of intrathecally administered anti-angiogenic agents in this setting have not previously been explored. A well-characterized animal model was used to evaluate the neurotoxicity of intraventricularly administered bevacizumab (BCM). Thirty-three New Zealand White Rabbits were studied. Subcutaneous reservoirs and ventricular catheters (SRVC) were placed in eight rabbits, which were randomized to receive weekly intraventricular saline with or without BCM for four weeks. These rabbits were euthanized on day 36 and the brains were examined by a blinded neuropathologist. Twenty-five additional rabbits underwent cisternal injection of VX2 carcinoma cells with or without a single dose of BCM and were followed for survival. No clinical manifestations of neurotoxicity were noted in rabbits treated with intraventricular BCM. Similarly, no evidence of BCM neurotoxicity was identified in autopsied animals. The median survival of evaluable rabbits with LC treated with intraventricular saline (N = 13) was 15 days compared to 18 days for the animals receiving VX2 and one dose of BCM (N = 12). Conclusion: Intraventricular BCM can be administered to rabbits without clinical or pathologic neurotoxicity. Survival following one dose of BCM in rabbits with LC should be cautiously interpreted given uncertainties regarding the dose, schedule, and limited expected benefit of this non-rabbit antibody. This neurotoxicity study provides safety data to allow phase I/II studies in humans with treatment refractory LC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Grossman SA, Krabak MJ (1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25(2):103–119

    Article  PubMed  CAS  Google Scholar 

  2. Chamberlain MC (2006) Neoplastic meningitis. Neurologist 12(4):179–187

    Article  PubMed  Google Scholar 

  3. NCCN Clinical Practice Guidelines in Oncology (2011). 34–40

  4. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186

    Article  PubMed  CAS  Google Scholar 

  5. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2(10):795–803

    Article  PubMed  CAS  Google Scholar 

  6. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039–2049

    Article  PubMed  CAS  Google Scholar 

  7. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D (2006) Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13(16):1845–1857

    Article  PubMed  CAS  Google Scholar 

  8. Reijneveld JC, Taphoorn MJ, Kerckhaert OA, Drixler TA, Boogerd W, Voest EE (2003) Angiostatin prolongs the survival of mice with leptomeningeal metastases. Eur J Clin Invest 33(1):76–81

    Article  PubMed  CAS  Google Scholar 

  9. Stockhammer G, Poewe W, Burgstaller S, Deisenhammer F, Muigg A, Kiechl S, Schmutzhard E, Maier H, Felber S, Schumacher P, Gunsilius E, Gastl G (2000) Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 54(8):1670–1676

    PubMed  CAS  Google Scholar 

  10. Mordenti J, Thomsen K, Licko V, Berleau L, Kahn JW, Cuthbertson RA, Duenas ET, Ryan AM, Schofield C, Berger TW, Meng YG, Cleland J (1999) Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol Sci 52(1):101–106

    Article  PubMed  CAS  Google Scholar 

  11. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27(5):536–544

    Article  PubMed  CAS  Google Scholar 

  12. Mordenti J, Thomsen K, Licko V, Chen H, Meng YG, Ferrara N (1999) Efficacy and concentration–response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 27(1):14–21

    Article  PubMed  CAS  Google Scholar 

  13. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550

    Article  PubMed  CAS  Google Scholar 

  14. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26(3):275–278

    Article  PubMed  Google Scholar 

  15. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114(12):2179–2182

    Article  PubMed  Google Scholar 

  16. Frank JA, Girton M, Dwyer AJ, Wright DC, Cohen PJ, Doppman JL (1988) Meningeal carcinomatosis in the VX2 rabbit tumor model: detection with Gd-DTPA-enhanced MR imaging. Radiology 167(3):825–829

    PubMed  CAS  Google Scholar 

  17. Phillips PC, Than TT, Cork LC, Hilton J, Carson BS, Colvin OM, Grochow LB (1992) Intrathecal 4-hydroperoxycyclophosphamide: neurotoxicity, cerebrospinal fluid pharmacokinetics, and antitumor activity in a rabbit model of VX2 leptomeningeal carcinomatosis. Cancer Res 52(22):6168–6174

    PubMed  CAS  Google Scholar 

  18. van der Flier M, Coenjaerts FE, Mwinzi PN, Rijkers E, Ruyken M, Scharringa J, Kimpen JL, Hoepelman AI, Geelen SP (2005) Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis. J Neuroimmunol 160(1–2):170–177

    Article  PubMed  Google Scholar 

  19. Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr (2006) Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 26(8):882–888. doi:10.1097/01.iae.0000230717.85319.f5

    Article  PubMed  Google Scholar 

  20. Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26(3):257–261

    Article  PubMed  Google Scholar 

  21. Kim WJ, Jeong HO, Chung SK (2010) The effect of bevacizumab on corneal neovascularization in rabbits. Korean J Ophthalmol 24(4):230–236. doi:10.3341/kjo.2010.24.4.230

    Article  PubMed  CAS  Google Scholar 

  22. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (3):363–372 e365. doi:10.1016/j.ophtha.2005.11.019

    Google Scholar 

  23. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142(1):1–9. doi:10.1016/j.ajo.2006.02.037

    Article  PubMed  CAS  Google Scholar 

  24. Amselem L, Cervera E, Diaz-Llopis M, Montero J, Garcia-Pous M, Udaondo P, Garcia-Delpech S, Salom D (2007) Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up. Eye 21(4):566–567. doi:10.1038/sj.eye.6702647

    PubMed  CAS  Google Scholar 

  25. Pullen RG (1985) Effect of ventricular tonicity upon cerebrospinal fluid production in rabbits. J Physiol 362:273–283

    PubMed  CAS  Google Scholar 

  26. Samphilipo MA Jr, Hassenbusch SJ, Grochow LB, Starr FL 3rd, Anderson JH (1987) A reservoir model for repeated CSF access in the rabbit. J Neurosci Methods 22(1):47–52

    Article  PubMed  Google Scholar 

  27. Langer R, Folkman J (1976) Polymers for the sustained release of proteins and other macromolecules. Nature 263(5580):797–800

    Article  PubMed  CAS  Google Scholar 

  28. Georges E, Breitburd F, Jibard N, Orth G (1985) Two Shope papillomavirus-associated VX2 carcinoma cell lines with different levels of keratinocyte differentiation and transplantability. J Virol 55(1):246–250

    PubMed  CAS  Google Scholar 

  29. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB (1999) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288(1):371–378

    PubMed  CAS  Google Scholar 

  30. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65(3):671–680

    PubMed  CAS  Google Scholar 

  31. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24(5):769–777

    Article  PubMed  CAS  Google Scholar 

  32. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342

    Article  PubMed  CAS  Google Scholar 

  33. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26(5):495–511

    Article  PubMed  Google Scholar 

  34. Zondor SD, Medina PJ (2004) Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 38(7–8):1258–1264

    PubMed  CAS  Google Scholar 

  35. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729

    Article  PubMed  CAS  Google Scholar 

  36. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259

    Article  PubMed  CAS  Google Scholar 

  37. Gordon MS, Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69(Suppl 3):25–33

    Article  PubMed  CAS  Google Scholar 

  38. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU (2006) Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Investg Ophthalmol Vis Sci 47(10):4569–4578

    Article  Google Scholar 

  39. Krohne TU, Eter N, Holz FG, Meyer CH (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146(4):508–512

    Article  PubMed  CAS  Google Scholar 

  40. Li K, Zhang G, Zhao J, Wang X, Li Y, Hu Y (2010) Vascular endothelial growth factor antisense oligonucleotides inhibit leptomeningeal metastasis in vivo. Med Oncol. 1–7. doi:10.1007/s12032-010-9580-6

  41. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG (2007) Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Investg Ophthalmol Vis Sci 48(4):1773–1781

    Article  Google Scholar 

  42. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7(9):987–989

    Article  PubMed  CAS  Google Scholar 

  43. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58–62

    Article  PubMed  CAS  Google Scholar 

  44. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64(11):3731–3736

    Article  PubMed  CAS  Google Scholar 

  45. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6(6):553–563

    PubMed  CAS  Google Scholar 

  46. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2):145–147. doi:10.1038/nm988

    Article  PubMed  CAS  Google Scholar 

  47. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY (2005) Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol: Off J Am Soc Clin Oncol 23(31):8136–8139. doi:10.1200/JCO.2005.02.5635

    Article  Google Scholar 

  48. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 21(1):60–65

    Article  CAS  Google Scholar 

  49. Levin VA, Landahl HD (1985) Pharmacokinetic approaches to drug distribution in the cerebrospinal fluid based on ventricular administration in beagle dogs. J Pharmacokinet Biopharm 13(4):387–403

    Article  PubMed  CAS  Google Scholar 

  50. Laske DW, Muraszko KM, Oldfield EH, DeVroom HL, Sung C, Dedrick RL, Simon TR, Colandrea J, Copeland C, Katz D, Greenfield L, Groves ES, Houston LL, Youle RJ (1997) Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery 41(5):1039–1049 discussion 1049–1051

    Article  PubMed  CAS  Google Scholar 

  51. Kramer K, Cheung NK, Humm J, DiResta G, Arbit E, Larson S, Finn R, Rosenblum M, Nguyen H, Gonzalez G, Liu C, Yang YF, Mendelsohn ME, Gillio AP (1997) Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates. J Neurooncol 35(2):101–111

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Priscilla K. Brastianos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brastianos, P.K., Brastianos, H.C., Hsu, W. et al. The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis. J Neurooncol 106, 81–88 (2012). https://doi.org/10.1007/s11060-011-0655-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-011-0655-9

Keywords

Navigation